{"transactions":[{"id":4627448,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":65992,"kind":"organization","name":"Weiss Asset Management LP","position":1,"cik":"0001357550","reported_name":"Weiss Asset Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":65993,"kind":"person","name":"WEISS ANDREW M","position":2,"cik":"0001357643","reported_name":"WEISS ANDREW M","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":123480,"kind":"organization","name":"WAM GP LLC","position":3,"cik":"0001504664","reported_name":"WAM GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Ordinary Share $0.00001 Par Value","published_at":"2026-09-28T19:20:28.000Z","date":"2026-09-23","kind":"other","planned":false,"acquired":false,"shares":7457060,"price":17,"value":126770020.0,"ownership":{"direct":false,"nature":"See Footnote 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each Ordinary Share $0.00001 Par Value of the Issuer held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."},{"field":"shares","element":"transactionShares","label":"F2","text":"Shares reported herein represent shares beneficially owned by two private investment funds for which Weiss Asset Management LP serves as investment manager. WAM GP LLC is the general partner of Weiss Asset Management LP and Andrew Weiss is the Manager of WAM GP LLC. All of Weiss Asset Management LP, WAM GP LLC, and Andrew Weiss disclaim beneficial ownership of the shares reported herein except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the cash portion of the consideration paid to shareholders upon the closing of the Merger."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001357550-26-000033","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000135755026000033/primary_doc.xml","form_type":"4"}},{"id":4626589,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13398,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626588,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626587,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626586,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22044,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626585,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.15,"expiration_date":"2032-04-25","underlying":"Ordinary Shares","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626584,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":20.35,"expiration_date":"2031-04-26","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626583,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":20.66,"expiration_date":"2030-06-30","underlying":"Ordinary Shares","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626582,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626581,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":58065,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":6009,"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626579,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:36:06.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13398,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001625377-26-000007","document":"form4-09252026_120902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1625377/000162537726000007/form4-09252026_120902.xml","form_type":"4"}},{"id":4626578,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:36:06.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001625377-26-000007","document":"form4-09252026_120902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1625377/000162537726000007/form4-09252026_120902.xml","form_type":"4"}},{"id":4626577,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:36:06.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001625377-26-000007","document":"form4-09252026_120902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1625377/000162537726000007/form4-09252026_120902.xml","form_type":"4"}},{"id":4626576,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:36:06.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22044,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001625377-26-000007","document":"form4-09252026_120902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1625377/000162537726000007/form4-09252026_120902.xml","form_type":"4"}},{"id":4626575,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:36:06.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.15,"expiration_date":"2032-04-25","underlying":"Ordinary Shares","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001625377-26-000007","document":"form4-09252026_120902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1625377/000162537726000007/form4-09252026_120902.xml","form_type":"4"}},{"id":4626574,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:36:06.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":20.35,"expiration_date":"2031-04-26","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001625377-26-000007","document":"form4-09252026_120902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1625377/000162537726000007/form4-09252026_120902.xml","form_type":"4"}},{"id":4626573,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:36:06.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":30.14,"expiration_date":"2030-04-27","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001625377-26-000007","document":"form4-09252026_120902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1625377/000162537726000007/form4-09252026_120902.xml","form_type":"4"}},{"id":4626572,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:36:06.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":23.85,"expiration_date":"2029-04-29","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001625377-26-000007","document":"form4-09252026_120902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1625377/000162537726000007/form4-09252026_120902.xml","form_type":"4"}},{"id":4626571,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:36:06.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":24.43,"expiration_date":"2028-04-30","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001625377-26-000007","document":"form4-09252026_120902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1625377/000162537726000007/form4-09252026_120902.xml","form_type":"4"}},{"id":4626570,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:36:06.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001625377-26-000007","document":"form4-09252026_120902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1625377/000162537726000007/form4-09252026_120902.xml","form_type":"4"}},{"id":4626569,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:36:06.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":74204,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":6009,"source":{"system":"sec-edgar","filing":"0001625377-26-000007","document":"form4-09252026_120902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1625377/000162537726000007/form4-09252026_120902.xml","form_type":"4"}},{"id":4626561,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13398,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626560,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626559,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626558,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22044,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626557,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.15,"expiration_date":"2032-04-25","underlying":"Ordinary Shares","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626556,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":20.35,"expiration_date":"2031-04-26","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626555,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":30.14,"expiration_date":"2030-04-27","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626554,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":23.85,"expiration_date":"2029-04-29","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626553,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":24.43,"expiration_date":"2028-04-30","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626552,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626551,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":91204,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":6009,"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626549,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13398,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626548,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."}],"balance_after":0,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626547,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."}],"balance_after":0,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626546,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22044,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."}],"balance_after":0,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626545,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."}],"balance_after":0,"derivative":{"exercise_price":9.87,"expiration_date":"2033-02-25","underlying":"Ordinary Shares","underlying_shares":32666},"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626544,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626543,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42137,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":6009,"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626540,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13398,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626539,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626538,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626537,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22044,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626536,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.15,"expiration_date":"2032-04-25","underlying":"Ordinary Shares","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626535,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":20.35,"expiration_date":"2031-04-26","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626534,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":30.14,"expiration_date":"2030-04-27","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626533,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":23.85,"expiration_date":"2029-04-29","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626532,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":24.43,"expiration_date":"2028-04-30","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626531,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":28.14,"expiration_date":"2028-02-12","underlying":"Ordinary Shares","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626530,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626529,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":74980,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":6009,"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626526,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":824,"kind":"person","name":"Winningham Rick E","position":1,"cik":"0001302443","reported_name":"Winningham Rick E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:27:42.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":515000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."}],"balance_after":0,"derivative":{"exercise_price":10.24,"expiration_date":"2032-02-24","underlying":"Ordinary Shares","underlying_shares":515000},"source":{"system":"sec-edgar","filing":"0001302443-26-000018","document":"form4-09252026_120938.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000130244326000018/form4-09252026_120938.xml","form_type":"4"}},{"id":4626525,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":824,"kind":"person","name":"Winningham Rick E","position":1,"cik":"0001302443","reported_name":"Winningham Rick E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:27:42.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":92567,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001302443-26-000018","document":"form4-09252026_120938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000130244326000018/form4-09252026_120938.xml","form_type":"4"}},{"id":4626524,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":824,"kind":"person","name":"Winningham Rick E","position":1,"cik":"0001302443","reported_name":"Winningham Rick E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:27:42.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23400,"ownership":{"direct":false,"nature":"As Custodian"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001302443-26-000018","document":"form4-09252026_120938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000130244326000018/form4-09252026_120938.xml","form_type":"4"}},{"id":4626523,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":824,"kind":"person","name":"Winningham Rick E","position":1,"cik":"0001302443","reported_name":"Winningham Rick E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:27:42.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":76875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a \"Company PSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001302443-26-000018","document":"form4-09252026_120938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000130244326000018/form4-09252026_120938.xml","form_type":"4"}},{"id":4626522,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":824,"kind":"person","name":"Winningham Rick E","position":1,"cik":"0001302443","reported_name":"Winningham Rick E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:27:42.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":151875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":76875,"source":{"system":"sec-edgar","filing":"0001302443-26-000018","document":"form4-09252026_120938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000130244326000018/form4-09252026_120938.xml","form_type":"4"}},{"id":4626521,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":824,"kind":"person","name":"Winningham Rick E","position":1,"cik":"0001302443","reported_name":"Winningham Rick E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:27:42.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1382272,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":228750,"source":{"system":"sec-edgar","filing":"0001302443-26-000018","document":"form4-09252026_120938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000130244326000018/form4-09252026_120938.xml","form_type":"4"}},{"id":4626520,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20249,"kind":"person","name":"Sawaf Aziz","position":1,"cik":"0001961289","reported_name":"Sawaf Aziz","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF FINANCIAL OFFICER"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:25:52.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23439,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a \"Company PSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001961289-26-000011","document":"form4-09252026_120949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1961289/000196128926000011/form4-09252026_120949.xml","form_type":"4"}},{"id":4626519,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20249,"kind":"person","name":"Sawaf Aziz","position":1,"cik":"0001961289","reported_name":"Sawaf Aziz","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF FINANCIAL OFFICER"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:25:52.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108436,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":23439,"source":{"system":"sec-edgar","filing":"0001961289-26-000011","document":"form4-09252026_120949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1961289/000196128926000011/form4-09252026_120949.xml","form_type":"4"}},{"id":4626518,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20249,"kind":"person","name":"Sawaf Aziz","position":1,"cik":"0001961289","reported_name":"Sawaf Aziz","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF FINANCIAL OFFICER"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:25:52.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":204966,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":131875,"source":{"system":"sec-edgar","filing":"0001961289-26-000011","document":"form4-09252026_120949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1961289/000196128926000011/form4-09252026_120949.xml","form_type":"4"}},{"id":4626517,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20434,"kind":"person","name":"Miller Aine","position":1,"cik":"0002012524","reported_name":"Miller Aine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, DEV & HEAD OF IRE OFFICE"}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:24:45.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":25.42,"expiration_date":"2030-03-01","underlying":"Ordinary Shares","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0002012524-26-000011","document":"form4-09252026_120941.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012524/000201252426000011/form4-09252026_120941.xml","form_type":"4"}},{"id":4626516,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20434,"kind":"person","name":"Miller Aine","position":1,"cik":"0002012524","reported_name":"Miller Aine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, DEV & HEAD OF IRE OFFICE"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:24:45.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":96718,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002012524-26-000011","document":"form4-09252026_120941.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012524/000201252426000011/form4-09252026_120941.xml","form_type":"4"}},{"id":4626515,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20434,"kind":"person","name":"Miller Aine","position":1,"cik":"0002012524","reported_name":"Miller Aine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, DEV & HEAD OF IRE OFFICE"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:24:45.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":93108,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":96718,"source":{"system":"sec-edgar","filing":"0002012524-26-000011","document":"form4-09252026_120941.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012524/000201252426000011/form4-09252026_120941.xml","form_type":"4"}},{"id":4626514,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20432,"kind":"person","name":"Grimaud Brett A.","position":1,"cik":"0001966698","reported_name":"Grimaud Brett A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GEN COUNSEL AND SECRETARY"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:23:05.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23439,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a \"Company PSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001966698-26-000011","document":"form4-09252026_120901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1966698/000196669826000011/form4-09252026_120901.xml","form_type":"4"}},{"id":4626513,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20432,"kind":"person","name":"Grimaud Brett A.","position":1,"cik":"0001966698","reported_name":"Grimaud Brett A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GEN COUNSEL AND SECRETARY"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:23:05.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":107812,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":23439,"source":{"system":"sec-edgar","filing":"0001966698-26-000011","document":"form4-09252026_120901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1966698/000196669826000011/form4-09252026_120901.xml","form_type":"4"}},{"id":4626512,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20432,"kind":"person","name":"Grimaud Brett A.","position":1,"cik":"0001966698","reported_name":"Grimaud Brett A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GEN COUNSEL AND SECRETARY"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:23:05.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":223917,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":131251,"source":{"system":"sec-edgar","filing":"0001966698-26-000011","document":"form4-09252026_120901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1966698/000196669826000011/form4-09252026_120901.xml","form_type":"4"}},{"id":4626511,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20424,"kind":"person","name":"Farnum Rhonda","position":1,"cik":"0001898490","reported_name":"Farnum Rhonda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, COMM & MEDICAL AFFAIRS"}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:21:53.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":25.64,"expiration_date":"2028-07-31","underlying":"Ordinary Shares","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001898490-26-000017","document":"form4-09252026_120949.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898490/000189849026000017/form4-09252026_120949.xml","form_type":"4"}},{"id":4626510,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20424,"kind":"person","name":"Farnum Rhonda","position":1,"cik":"0001898490","reported_name":"Farnum Rhonda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, COMM & MEDICAL AFFAIRS"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:21:53.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":89062,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001898490-26-000017","document":"form4-09252026_120949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898490/000189849026000017/form4-09252026_120949.xml","form_type":"4"}},{"id":4626509,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20424,"kind":"person","name":"Farnum Rhonda","position":1,"cik":"0001898490","reported_name":"Farnum Rhonda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, COMM & MEDICAL AFFAIRS"}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:21:53.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":124414,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":89062,"source":{"system":"sec-edgar","filing":"0001898490-26-000017","document":"form4-09252026_120949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898490/000189849026000017/form4-09252026_120949.xml","form_type":"4"}},{"id":4621859,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20424,"kind":"person","name":"Farnum Rhonda","position":1,"cik":"0001898490","reported_name":"Farnum Rhonda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, COMM & MEDICAL AFFAIRS"}}],"security":"Ordinary Shares","published_at":"2026-09-17T21:52:04.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":6657,"price":17.0342,"value":113396.6694,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices from $17.02 to $17.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":213476,"source":{"system":"sec-edgar","filing":"0001898490-26-000014","document":"form4-09172026_090959.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898490/000189849026000014/form4-09172026_090959.xml","form_type":"4"}},{"id":4621858,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20424,"kind":"person","name":"Farnum Rhonda","position":1,"cik":"0001898490","reported_name":"Farnum Rhonda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, COMM & MEDICAL AFFAIRS"}}],"security":"Ordinary Shares","published_at":"2026-09-17T21:52:04.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":3328,"price":17.0343,"value":56690.1504,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices from $17.02 to $17.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":220133,"source":{"system":"sec-edgar","filing":"0001898490-26-000014","document":"form4-09172026_090959.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898490/000189849026000014/form4-09172026_090959.xml","form_type":"4"}},{"id":4621857,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20424,"kind":"person","name":"Farnum Rhonda","position":1,"cik":"0001898490","reported_name":"Farnum Rhonda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, COMM & MEDICAL AFFAIRS"}}],"security":"Ordinary Shares","published_at":"2026-09-17T21:52:04.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":3329,"price":17.0341,"value":56706.5189,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices from $17.02 to $17.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":223461,"source":{"system":"sec-edgar","filing":"0001898490-26-000014","document":"form4-09172026_090959.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898490/000189849026000014/form4-09172026_090959.xml","form_type":"4"}},{"id":677219,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":824,"kind":"person","name":"Winningham Rick E","position":1,"cik":"0001302443","reported_name":"Winningham Rick E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Ordinary Shares","published_at":"2026-08-24T22:09:15.000Z","date":"2026-08-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":20034,"price":16.95,"value":339576.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":1611022,"source":{"system":"sec-edgar","filing":"0001302443-26-000012","document":"form4-08242026_100811.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302443/000130244326000012/form4-08242026_100811.xml","form_type":"4"}},{"id":677109,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20249,"kind":"person","name":"Sawaf Aziz","position":1,"cik":"0001961289","reported_name":"Sawaf Aziz","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF FINANCIAL OFFICER"}}],"security":"Ordinary Shares","published_at":"2026-08-24T22:07:23.000Z","date":"2026-08-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":8112,"price":16.95,"value":137498.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":336841,"source":{"system":"sec-edgar","filing":"0001961289-26-000008","document":"form4-08242026_100819.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000196128926000008/form4-08242026_100819.xml","form_type":"4"}},{"id":677628,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20434,"kind":"person","name":"Miller Aine","position":1,"cik":"0002012524","reported_name":"Miller Aine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, DEV & HEAD OF IRE OFFICE"}}],"security":"Ordinary Shares","published_at":"2026-08-24T22:04:40.000Z","date":"2026-08-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":6258,"price":16.95,"value":106073.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":189826,"source":{"system":"sec-edgar","filing":"0002012524-26-000008","document":"form4-08242026_100836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012524/000201252426000008/form4-08242026_100836.xml","form_type":"4"}},{"id":677621,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20432,"kind":"person","name":"Grimaud Brett A.","position":1,"cik":"0001966698","reported_name":"Grimaud Brett A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GEN COUNSEL AND SECRETARY"}}],"security":"Ordinary Shares","published_at":"2026-08-24T22:02:45.000Z","date":"2026-08-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":7952,"price":16.95,"value":134786.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":355168,"source":{"system":"sec-edgar","filing":"0001966698-26-000008","document":"form4-08242026_100841.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1966698/000196669826000008/form4-08242026_100841.xml","form_type":"4"}},{"id":677586,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20424,"kind":"person","name":"Farnum Rhonda","position":1,"cik":"0001898490","reported_name":"Farnum Rhonda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, COMM & MEDICAL AFFAIRS"}}],"security":"Ordinary Shares","published_at":"2026-08-24T22:00:15.000Z","date":"2026-08-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":5667,"price":16.95,"value":96055.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":226790,"source":{"system":"sec-edgar","filing":"0001898490-26-000012","document":"form4-08242026_100811.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898490/000189849026000012/form4-08242026_100811.xml","form_type":"4"}},{"id":712793,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":31459,"kind":"person","name":"Samaha Eli","position":1,"cik":"0001877589","reported_name":"Samaha Eli","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COM","published_at":"2026-07-08T20:13:43.000Z","date":"2026-07-07","kind":"sale","planned":false,"acquired":false,"shares":5564,"price":17.1712,"value":95540.5568,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by funds managed by Madison Avenue Partners, LP.  The Reporting Person is the managing partner of Madison Avenue Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein.  The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities."}],"balance_after":9167489,"source":{"system":"sec-edgar","filing":"0001877589-26-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877589/000187758926000002/primary_doc.xml","form_type":"4"}},{"id":712792,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":31459,"kind":"person","name":"Samaha Eli","position":1,"cik":"0001877589","reported_name":"Samaha Eli","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COM","published_at":"2026-07-08T20:13:43.000Z","date":"2026-07-06","kind":"sale","planned":false,"acquired":false,"shares":1400,"price":17.04,"value":23856.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by funds managed by Madison Avenue Partners, LP.  The Reporting Person is the managing partner of Madison Avenue Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein.  The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities."}],"balance_after":9173053,"source":{"system":"sec-edgar","filing":"0001877589-26-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877589/000187758926000002/primary_doc.xml","form_type":"4"}},{"id":721416,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":31459,"kind":"person","name":"Samaha Eli","position":1,"cik":"0001877589","reported_name":"Samaha Eli","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COM","published_at":"2026-07-01T23:33:47.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":37799,"price":17.0012,"value":642628.3588,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.00 to $17.015, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by funds managed by Madison Avenue Partners, LP.  The Reporting Person is the managing partner of Madison Avenue Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein.  The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities."}],"balance_after":9174453,"source":{"system":"sec-edgar","filing":"0001877589-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1877589/000187758926000001/primary_doc.xml","form_type":"4"}},{"id":721415,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":31459,"kind":"person","name":"Samaha Eli","position":1,"cik":"0001877589","reported_name":"Samaha Eli","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COM","published_at":"2026-07-01T23:33:47.000Z","date":"2026-06-30","kind":"sale","planned":false,"acquired":false,"shares":25027,"price":17.133,"value":428787.591,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.13 to $17.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by funds managed by Madison Avenue Partners, LP.  The Reporting Person is the managing partner of Madison Avenue Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein.  The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities."}],"balance_after":9212252,"source":{"system":"sec-edgar","filing":"0001877589-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877589/000187758926000001/primary_doc.xml","form_type":"4"}},{"id":721414,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":31459,"kind":"person","name":"Samaha Eli","position":1,"cik":"0001877589","reported_name":"Samaha Eli","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COM","published_at":"2026-07-01T23:33:47.000Z","date":"2026-06-29","kind":"sale","planned":false,"acquired":false,"shares":273871,"price":17.2349,"value":4720139.2979,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.07 to $17.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by funds managed by Madison Avenue Partners, LP.  The Reporting Person is the managing partner of Madison Avenue Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein.  The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities."}],"balance_after":9237279,"source":{"system":"sec-edgar","filing":"0001877589-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877589/000187758926000001/primary_doc.xml","form_type":"4"}},{"id":729321,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20434,"kind":"person","name":"Miller Aine","position":1,"cik":"0002012524","reported_name":"Miller Aine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, DEV & HEAD OF IRE OFFICE"}}],"security":"Ordinary Shares","published_at":"2026-06-23T21:49:21.000Z","date":"2026-06-19","kind":"grant","planned":false,"acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":196084,"source":{"system":"sec-edgar","filing":"0002012524-26-000006","document":"form4-06232026_090617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012524/000201252426000006/form4-06232026_090617.xml","form_type":"4"}},{"id":734416,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20424,"kind":"person","name":"Farnum Rhonda","position":1,"cik":"0001898490","reported_name":"Farnum Rhonda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, COMM & MEDICAL AFFAIRS"}}],"security":"Ordinary Shares","published_at":"2026-06-17T23:56:36.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":6657,"price":16.3856,"value":109078.9392,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices from $16.21 to $16.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":232457,"source":{"system":"sec-edgar","filing":"0001898490-26-000010","document":"form4-06172026_110631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898490/000189849026000010/form4-06172026_110631.xml","form_type":"4"}},{"id":734415,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20424,"kind":"person","name":"Farnum Rhonda","position":1,"cik":"0001898490","reported_name":"Farnum Rhonda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, COMM & MEDICAL AFFAIRS"}}],"security":"Ordinary Shares","published_at":"2026-06-17T23:56:36.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":3328,"price":16.3838,"value":54525.2864,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices from $16.21 to $16.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":239114,"source":{"system":"sec-edgar","filing":"0001898490-26-000010","document":"form4-06172026_110631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898490/000189849026000010/form4-06172026_110631.xml","form_type":"4"}},{"id":734414,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20424,"kind":"person","name":"Farnum Rhonda","position":1,"cik":"0001898490","reported_name":"Farnum Rhonda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, COMM & MEDICAL AFFAIRS"}}],"security":"Ordinary Shares","published_at":"2026-06-17T23:56:36.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":3329,"price":16.3902,"value":54562.9758,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices from $16.21 to $16.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":242442,"source":{"system":"sec-edgar","filing":"0001898490-26-000010","document":"form4-06172026_110631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898490/000189849026000010/form4-06172026_110631.xml","form_type":"4"}},{"id":735843,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-17T01:40:59.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":13398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":13398,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001589602-26-000002","document":"form4-06172026_010655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000158960226000002/form4-06172026_010655.xml","form_type":"4"}},{"id":735842,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-17T01:40:59.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":6009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80989,"source":{"system":"sec-edgar","filing":"0001589602-26-000002","document":"form4-06172026_010655.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000158960226000002/form4-06172026_010655.xml","form_type":"4"}},{"id":735841,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-17T01:39:42.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":13398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":13398,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001833453-26-000006","document":"form4-06172026_010638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000183345326000006/form4-06172026_010638.xml","form_type":"4"}},{"id":735840,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-17T01:39:42.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":6009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":48146,"source":{"system":"sec-edgar","filing":"0001833453-26-000006","document":"form4-06172026_010638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000183345326000006/form4-06172026_010638.xml","form_type":"4"}},{"id":735984,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-17T01:37:40.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":13398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":13398,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001199297-26-000003","document":"form4-06172026_010636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000119929726000003/form4-06172026_010636.xml","form_type":"4"}},{"id":735983,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-17T01:37:40.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":6009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":97213,"source":{"system":"sec-edgar","filing":"0001199297-26-000003","document":"form4-06172026_010636.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000119929726000003/form4-06172026_010636.xml","form_type":"4"}},{"id":735839,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-17T01:36:48.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":13398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":13398,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001625377-26-000004","document":"form4-06172026_010644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000162537726000004/form4-06172026_010644.xml","form_type":"4"}},{"id":735838,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":37595,"kind":"person","name":"O'Connor Donal","position":1,"cik":"0001625377","reported_name":"O'Connor Donal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-17T01:36:48.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":6009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80213,"source":{"system":"sec-edgar","filing":"0001625377-26-000004","document":"form4-06172026_010644.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000162537726000004/form4-06172026_010644.xml","form_type":"4"}},{"id":736003,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-17T01:35:54.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":13398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":13398,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001270734-26-000004","document":"form4-06172026_010650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000127073426000004/form4-06172026_010650.xml","form_type":"4"}},{"id":736002,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-17T01:35:54.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":6009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":64074,"source":{"system":"sec-edgar","filing":"0001270734-26-000004","document":"form4-06172026_010650.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000127073426000004/form4-06172026_010650.xml","form_type":"4"}},{"id":765590,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":824,"kind":"person","name":"Winningham Rick E","position":1,"cik":"0001302443","reported_name":"Winningham Rick E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Ordinary Shares","published_at":"2026-05-22T22:27:58.000Z","date":"2026-05-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":20038,"price":16.55,"value":331628.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":1631056,"source":{"system":"sec-edgar","filing":"0001302443-26-000006","document":"form4-05222026_100553.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302443/000130244326000006/form4-05222026_100553.xml","form_type":"4"}},{"id":765408,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20249,"kind":"person","name":"Sawaf Aziz","position":1,"cik":"0001961289","reported_name":"Sawaf Aziz","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF FINANCIAL OFFICER"}}],"security":"Ordinary Shares","published_at":"2026-05-22T22:25:10.000Z","date":"2026-05-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":8670,"price":16.55,"value":143488.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":344953,"source":{"system":"sec-edgar","filing":"0001961289-26-000006","document":"form4-05222026_100506.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000196128926000006/form4-05222026_100506.xml","form_type":"4"}},{"id":766296,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20434,"kind":"person","name":"Miller Aine","position":1,"cik":"0002012524","reported_name":"Miller Aine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, DEV & HEAD OF IRE OFFICE"}}],"security":"Ordinary Shares","published_at":"2026-05-22T22:22:11.000Z","date":"2026-05-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":6827,"price":16.55,"value":112986.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":177334,"source":{"system":"sec-edgar","filing":"0002012524-26-000004","document":"form4-05222026_100507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012524/000201252426000004/form4-05222026_100507.xml","form_type":"4"}},{"id":766272,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":20432,"kind":"person","name":"Grimaud Brett A.","position":1,"cik":"0001966698","reported_name":"Grimaud Brett A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GEN COUNSEL AND SECRETARY"}}],"security":"Ordinary Shares","published_at":"2026-05-22T22:19:55.000Z","date":"2026-05-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":8829,"price":16.55,"value":146119.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction."}],"balance_after":363120,"source":{"system":"sec-edgar","filing":"0001966698-26-000006","document":"form4-05222026_100551.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1966698/000196669826000006/form4-05222026_100551.xml","form_type":"4"}}],"next_cursor":"2026-05-22T22:19:55.000000Z,766272"}